All In Biotech

Drug Trial Radar · NCT05218655

A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

An Open-Label, Safety Study for Previously Treated Vatiquinone (PTC743) Subjects With Inherited Mitochondrial Disease

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

101

Actual

Start

Jun 22, 2022

Primary completion

Apr 15, 2025

Study completion Apr 15, 2025

Sponsor

Lead sponsor
PTC TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan. The study will continue until vatiquinone becomes commercially available or the program is terminated.

Conditions

  • Inherited Mitochondrial Disease

Interventions

  • VatiquinoneDrug

    Vatiquinone will be administered per dose and schedule specified in the arm description.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline (Day 1) up to 30 days after last dose of study drug (956 days)

Locations

26 sites in 7 countries. Site status is shown where the registry gives one.

  • University of California, San Diego Altman Clinical and Translational Research Institute

    La Jolla, California

  • Stanford University

    Stanford, California

  • Yale Medicine

    New Haven, Connecticut

  • Children's National

    Washington D.C., District of Columbia

  • Child Neurology Center of Northwest Florida

    Gulf Breeze, Florida

  • The Johns Hopkins University

    Baltimore, Maryland

  • Columbia University Medical Center - CUMC

    New York, New York

  • Akron Children's Hospital

    Akron, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Children's Hospital of Philadelphia - CHOP

    Philadelphia, Pennsylvania

  • Medical University of South Carolina - MUSC

    Charleston, South Carolina

  • Baylor College of Medicine

    Houston, Texas

  • UT Health The University of Texas

    Houston, Texas

  • Seattle Children Hospital

    Seattle, Washington

  • Chu Angers

    Angers, France

  • CHU Montpellier - Hopital Saint-Eloi

    Montpellier, France

  • Hopital Necker-Enfants Malades

    Paris, France

  • Hôpital de Hautepierre - Hôpitaux Universitaires de Strasbourg

    Strasbourg, France

  • Ospedale Pediatrico Bambino Gesù

    Roma, Italy

  • PTC Clinical Site

    Japanese City, Japan

  • Instytut Pomnik - Centrum Zdrowia Dziecka

    Warsaw, Poland

  • Hospital Sant Joan de Déu

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Ruber Internacional

    Madrid, Spain

  • Great Ormond Street Hospital for Children NHS Foundation Trust

    London, United Kingdom

  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.